CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL SLL from umrd Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Rajat Bannerji speaks to ecancer about the CAPTIVATE study. nnIt is a trial investigating a fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL. nnInitially, he explains the background of the study. Dr Bannerji then discusses the methodology and results of the study. nnHe mentions that first-line I+V is an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides deep, durable responses in patients with CLL/SLL, including those with genomic high-